[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"implant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:implant":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,86,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100494880","carotid-implants-for-prevention-of-stroke-recurrence-from-large-vessel-occlusion-in-atrial-fibrillation-patients-treated-with-oral-anticoagulation-100494880",false,"NCT05723926","Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation","INTERCEPT","Inclusion Criteria:\n\n1. Documented history of clinical AF\n2. History of ischemic (i.e. non-hemorrhagic) stroke including symptoms of stroke resolving within 24 hours with positive neuro-imaging, meeting one of the following criteria:\n\n   Group 1: Patient was on OAC at time of index stroke, with index stroke occurring \\\u003C 6 week from enrollment Group 2: Patient was not on OAC at time of stroke, with index stroke occurring \\\u003C 6 weeks from enrollment Group 3: Patient was on OAC at time of index stroke, with index stroke occurring 6 to 52 weeks from enrollment\n3. Planned use of a Vitamin K antagonist (VKA) or a direct oral anticoagulant (DOAC) for the duration of the trial\n4. Patient able to tolerate single antiplatelet therapy in addition to oral anticoagulation for 6 months, in the opinion of the investigator\n5. Bilateral ultrasound or angiogram demonstrating all of the following:\n\n   1. Inner common carotid artery diameter range: ≥5.3 mm and ≤8.8 mm\n   2. Accessibility: up to 40 mm from skin to common carotid artery center\n   3. Implantation segment free of any atherosclerotic disease\n   4. Absence of carotid dissection or pre-existing stent(s) in common carotid artery\n   5. Absence of ≥50% stenosis of the internal carotid arteries as seen on ultrasound or angiography (CTA, MRA or DSA)\n\n   i. For ultrasound, calculate the percentage of carotid stenosis using the Society of Radiologists in Ultrasound Consensus Criteria for Carotid Stenosis, where ≥50% stenosis is defined by internal carotid artery peak systolic velocity of ≥125 cm\u002Fsec, internal\u002Fcommon carotid peak systolic velocity ratio of 2 or more and end diastolic velocity of ≥40 cm\u002Fsec, or evidence of near occlusion.\n\n   ii. For angiography, calculate the percentage of carotid stenosis using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria (\\[D - N\\]\u002FD x 100, where N is the luminal diameter at the site of maximal narrowing and D is the diameter of normal distal internal carotid artery beyond the bulb where the artery walls are parallel.\n6. Provision of informed consent\n\nExclusion Criteria:\n\n1. Contraindication to oral anticoagulation (e.g. history of intracranial hemorrhage, known hereditary or acquired coagulation disorders, or recurrent major bleeding)\n2. Contraindication to additional single antiplatelet therapy for 6 months from randomization\n3. Previously documented 50% or greater stenosis, or high-risk plaque in the opinion of the investigator, of the common carotid, internal carotid, subclavian, vertebral, or intracranial arteries that has not been treated with a revascularization procedure (i.e. stent or angioplasty)\n4. Visualized active (acute\u002Fsubacute) cervical or intracranial arterial thrombus (i.e. free-floating) on computed tomography (CT), magnetic resonance (MR), or digital subtraction (DS) angiography that is at risk of causing additional stroke\u002Fbrain injury\n5. Previously documented aneurysm of the internal carotid artery or its branches (i.e. ophthalmic, posterior communicating, anterior choroidal, anterior cerebral and middle cerebral arteries) that is 6 mm or greater in diameter.\n6. Prior surgery or radiation of the neck at the implantation segment\n7. Pre-existing percutaneous left atrial appendage occlusion device that was implanted after most recent ischemic stroke\n8. Planned left atrial appendage occlusion procedure\n9. Female who is pregnant or non-postmenopausal female who is not willing to use an effective method of birth control during duration of the trial\n10. Overt systemic infection\n11. Known sensitivity to nickel or titanium metals, or their alloys\n12. Active participation in another investigational drug or device treatment trial\n13. Any other condition that in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the trial","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO). This randomized control trial aims to address this unmet need by testing whether use of bilateral carotid filter implants in addition to OAC will reduce the risk of stroke in AF patients with recent (e.g. within 12 months) ischemic stroke vs. only OAC.",[26,27,28,29],"Atrial Fibrillation","Oral Anticoagulation","Stroke","Implant",[31,32,33,34],"Filter","Ischemic stroke","NOAC","LVO","RECRUITING","2026-06-07",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":39},"2026-01-09",{"date":43,"type":20},"2030-10-20",{"name":45,"class":46},"Javelin Medical","INDUSTRY",7,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100631180","safety-and-performance-of-a-pelvic-floor-mesh-implant-for-laparoscopic-sacrocolpopexy-progynious-100631180","NCT07497321","Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)","ProGYNious","Inclusion Criteria:\n\n* Subject is a candidate for surgical repair of pelvic organ prolapse by ProGYNious implant according to the indication of the product under evaluation\n* Symptomatic pelvic organ prolapse with POP-Q \\>= 2\n* Age \\>18 years and ≤ 80years\n* Subject is willing and able to cooperate with follow-up examinations\n* Subject has been informed of the study procedures and the treatment and has signed an informed consent form\n\nExclusion Criteria:\n\n* previous or concurrent cancer which may affect the successful treament with laparoscopic mesh\n* known or suspected hypersensitivity to ProGYNious mesh or a component of ProGYNious mesh (Polypropylene)\n* known severe osteoporosis\n* pregnancy, suspected pregnancy and breastfeeding\n* bleeding of unknown cause in the genital area\n* previously irradiated patients in the pelvic area\n* drug or medication abuse, medical, psychological or social circumstances that could affect the patient's participation in the study or the evaluation of the study results\n* Any previous interventions with surgical mesh for pelvic organ prolapse and\u002For urinary incontinence\n* Unable to understand study requirements or is unable to comply with follow-up schedule\n* Contraindicated according to the instruction for use of the device\n* patients with an increased risk of infection or impaired wound healing (e.g. Diabetes mellitus with HbA1c \\>10, systemic autoimmune diseases, etc.)\n* concomitant Sling\u002FTVT procedure\n* life expectancy lower than follow-up period (e.g. ASA 4)\n* non-symptomatic pelvic organ prolapse\n* chronic pain syndrome\n* chronic respiratory disease (e.g. COPD, chronic cough)","FEMALE","80 Years",{"count":58,"type":20},100,[23],"The purpose of this clinical investigation is to collect clinical data about the ProGYNious Mesh based on a prospective clinical investigation. The primary objective is to verify the treatment outcome and success of the ProGYNious mesh implant in pelvic organ prolapse repair. The secondary objective is to confirm the safety, risks, complications and quality of life of ProGYNious as an implant for pelvic organ prolapse repair.",[62,63,64,65,66,67,68,29],"Pelvic Organ Prolapse (POP)","Synthetic Mesh","Laparoscopic Surgery","Gynecologic Laparoscopic Surgery","Sacrocolpopexy","Pelvic Floor Prolapse","Pelvic Floor",[53,70,71,72,73,74],"A.M.I.","AMI","Agency for Medical Innovation","Y Mesh","Progyn","NOT_YET_RECRUITING","2026-03-24",{"date":78,"type":39},"2026-03-27",{"date":80,"type":20},"2026-04-15",{"date":82,"type":20},"2028-09-30",{"name":84,"class":46},"A.M.I. Agency for Medical Innovations GmbH",5,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100612104","healing-outcomes-of-peri-implant-soft-tissues-with-different-healing-abutments-100612104","NCT07249242","Healing Outcomes of Peri-implant Soft Tissues With Different Healing Abutments","Healing Outcomes of Peri-implant Soft Tissues With Customized Healing Abutments in Immediate and Delayed Implant Placement Protocols: a Pilot Study","Inclusion Criteria:\n\n1. Patients of record at TUSDM who are over 18 years of age\n2. Implants placed as immediate or delayed with a torque of ≥ 35 Ncm eligible to receive a healing abutment left exposed to heal;\n3. Site of implant placement not requiring soft tissue augmentation at the time of healing abutment placement\n4. Sufficient mesial, distal space (7mm for anterior teeth and premolar and 8-9mm for molars) and interocclusal space (7-8mm for screw and cement retained crowns) for definitive restorations (12).\n\nExclusion Criteria:\n\n1. Unable to give consent\n2. active periodontal disease\n3. Heavy smoker\n4. Pregnant\n5. Active infection at implant site",{"count":94,"type":20},48,[23],"The purpose of this study is to compare how well our research participants heal with two different kind of healing abutments used. One is pre-fabricated, meaning it is made to fit anyone, and the other is customized to fit the subject specifically. Much of what will occur is 'standard of care' meaning it is part of a subject's typical dental treatment and the research team wants to just look at the data for this research study, as well.",[29],"2026-01-21",{"date":100,"type":39},"2026-01-22",{"date":100,"type":39},{"date":103,"type":20},"2028-01-01",{"name":105,"class":106},"Tufts University","OTHER",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":107},"100607365","zinc-incorporated-bovine-derived--hydroxyappatite-xenograft-in-immediately-placed-implant-100607365","NCT07187609","Zinc Incorporated Bovine Derived- Hydroxyappatite Xenograft in Immediately Placed Implant","Clinical and Radiographic Evaluation of Zinc Incorporated Bovine Derived- Hydroxyappatite Xenograft in Immediately Placed Implant: A Randomized Clinical Study","Inclusion Criteria:\n\n* Adult(male or female) patients between the ages of 21 -50 years who requiring the replacement of one or more non-restorable teeth in the mandible which will be indicated for extraction.\n* Adequate bone dimensions at the implant site with ridge width of at least 6 mm, the availability of at least 3mm of sound subapical bone, the presence of an intact labial bone plate, and no evidance of periapical infection on cone beam computed tomography or clinically\n* The peri-implant gaps larger than 1.5 mm will be included.\n* All patients will be physically healthy with no medical history of any systemic disease.\n\nExclusion Criteria:\n\n* Smokers.\n* Patients with para functional habits such as bruxism and clenching\n* Poorly controlled systemic diseases which preclude local anesthesia or surgical procedures\n* Patients undergoing chemotherapy or radiotherapy and immuno-compromised patients.\n* Pregnant \u002Flactating women.\n* Patients that are allergic to zinc\n* Patients on antibiotic therapy in the pervious 6 months",true,"21 Years","50 Years",{"count":119,"type":20},16,[23],"The aim of this study is to evaluate Clinical and radiographic effect of zinc incorporated bovine derived hydroxyapatite xenograft and bovine hydroxyapatite xenograft alone for immediately placed implant",[29,123],"Zinc Status",[125,29,126],"bone grafts","zinc in corporated bovine drived hydroxyappatite","2025-09-18",{"date":129,"type":39},"2025-09-23",{"date":131,"type":39},"2025-08-13",{"date":133,"type":20},"2026-11-08",{"name":135,"class":106},"Suez Canal University"]